Cns Pharmaceuticals (CNSP)Director bought ~$10K

~$10K

Approx. value · 2,000 sh @ $5.00

2,000

Holds after · shares reported

Traded

May 18, 2026

Filed

Aug 18, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. May 4, 2026Company filing · Form 8-K · Material agreement, Unregistered sharesChanged a top executive or board member, and signed an important agreement (and 1 more item)“On May 4, 2026, Jerzy (George) Gumulka resigned as a member of the Company’s Board of Directors (the “Board”) . Mr. Gumulka’s resignation from the Board was not a result of any disagreement with the Company on any matter relating to the Company's operations, policies or practices.”
2. May 18, 2026 · this disclosureInsider · First insider buy since Feb 2024Director purchased ~$10K of CNSP shares in the open market

What came next

1. May 18, 2026Insider · First insider buy since Feb 2024Director purchased ~$34K of CNSP shares in the open market

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Cns Pharmaceuticals

For Cns Pharmaceuticals, OQRO holds 1 insider filing (SEC Form 4 or Form 144) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its CNSP page.

How this filing works

• SEC Form 4
• Open-market purchase
• Rule 10b5-1 trading plans

Other disclosures at Cns Pharmaceuticals

• SEC Form 4May 20, 2026

Everything OQRO holds on this company is on its CNSP page.